BCAL Diagnostics Limited (ASX:BDX – Get Free Report) insider Jayne Shaw purchased 125,000 shares of BCAL Diagnostics stock in a transaction that occurred on Friday, September 13th. The shares were purchased at an average cost of A$0.12 ($0.08) per share, with a total value of A$14,375.00 ($9,712.84).
BCAL Diagnostics Price Performance
The company has a debt-to-equity ratio of 17.74, a quick ratio of 6.70 and a current ratio of 3.60.
BCAL Diagnostics Company Profile
Further Reading
- Five stocks we like better than BCAL Diagnostics
- How to Start Investing in Real Estate
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- The Basics of Support and Resistance
- MarketBeat Week in Review – 9/16 – 9/20
- What Makes a Stock a Good Dividend Stock?
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for BCAL Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BCAL Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.